| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/11/2013 | US8460939 Method for producing purified hematinic iron-saccharidic complex and product produced |
| 06/11/2013 | US8460917 Lactobacillus strains |
| 06/11/2013 | US8460710 Antibiotic product, use and formulation thereof |
| 06/11/2013 | US8460694 Solvent/polymer solutions as suspension vehicles |
| 06/11/2013 | US8460675 Viral chemokine-antigen fusion proteins |
| 06/11/2013 | US8460646 Methods and compositions for treating mammalian nerve tissue injuries |
| 06/11/2013 | CA2672985C Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia |
| 06/11/2013 | CA2498004C Compositions and methods for the diagnosis and treatment of tumor |
| 06/11/2013 | CA2473864C Composition for use in treating patients suffering from movement disorder |
| 06/11/2013 | CA2473158C Treatment of rheumatoid arthritis using imatinib |
| 06/11/2013 | CA2427334C Methods and compositions for the treatment of diseases of the eye |
| 06/11/2013 | CA2405473C Dna molecules encoding ligand gated ion channels from dermacentor variabilis |
| 06/11/2013 | CA2400410C Antimicrobial compounds and formulations |
| 06/06/2013 | WO2013082541A1 Method of preventing acute graft-versus-host disease using oral beclomethasone dipropionate |
| 06/06/2013 | WO2013081154A1 Agent for reducing adverse side effects of kinase inhibitor |
| 06/06/2013 | WO2013081143A1 Drug containing carrier into cell for forming immune complex |
| 06/06/2013 | WO2013080999A1 Agent for inhibiting expression of npc1l1 and/or lipg mrna and agent for preventing and/or treating obesity |
| 06/06/2013 | WO2013080366A1 Sterilizer, oral sterilizer, sterilization method, sterilization apparatus, and sterilizer evaluation method |
| 06/06/2013 | WO2013080148A1 A process for the preparation of solid dispersion of lopinavir and ritonavir |
| 06/06/2013 | WO2013079205A1 Low dose therapeutic use of glyceryl tri-(4-phenylbutyrate) |
| 06/06/2013 | US20130143962 Adamantyl Derivatives as Therapeutic Agents |
| 06/06/2013 | US20130143960 Novel serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity |
| 06/06/2013 | US20130143950 Compounds and Methods for the Treatment of Cancer |
| 06/06/2013 | US20130143944 Chemo- and radiation-sensitization of cancer by antisense trpm-2 oligodeoxynucleotides |
| 06/06/2013 | US20130143937 Chlorthalidone combinations |
| 06/06/2013 | US20130143934 Agent for regeneration and/or protection of nerves |
| 06/06/2013 | US20130143930 Activation of amp-protein activated kinase by oxaloacetate compounds |
| 06/06/2013 | US20130143918 Solid Forms of (R)-1(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)-N-(1-(2,3-Dihydroxypropyl-6-Fluoro-2-(1-Hydroxy-2-Methylpropan-2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| 06/06/2013 | US20130143906 Substituted pyrimidinone-phenyl-pyrimidinyl compounds |
| 06/06/2013 | US20130143902 Compositions and methods of treating a proliferative disease with a quinazolinone derivative |
| 06/06/2013 | US20130143899 Compounds and compositions as protein kinase inhibitors |
| 06/06/2013 | US20130143898 Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| 06/06/2013 | US20130143896 Isoxazolo-quinazolines as modulators of protein kinase activity |
| 06/06/2013 | US20130143879 Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 06/06/2013 | US20130143873 Diazoxide For Use In The Treatment Of Amyotrophic Lateral Sclerosis (ALS) |
| 06/06/2013 | US20130143868 Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
| 06/06/2013 | US20130143867 Acamprosate formulations, methods of using the same, and combinations comprising the same |
| 06/06/2013 | US20130143861 Methods for treating atrial fibrillation |
| 06/06/2013 | US20130143859 Novel prolylcarboxypeptidase inhibitors |
| 06/06/2013 | US20130143843 Aryl dihydropyridinone and piperidinone mgat2 inhibitors |
| 06/06/2013 | US20130143800 Combination therapies to treat diabetes |
| 06/06/2013 | US20130143797 Glycoproteins Having Lipid Mobilizing Properties an Therapeutic Uses Thereof |
| 06/06/2013 | US20130143793 Peptide conjugates of glp-1 receptor agonists and gastrin and their use |
| 06/06/2013 | US20130142888 N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament |
| 06/06/2013 | US20130142882 Methods and compositions for treatment, modification and management of bone cancer pain |
| 06/06/2013 | US20130142875 Methods and compositions for treating prostate cancer |
| 06/06/2013 | US20130142867 Cancer-targeting peptides and uses thereof in cancer treatment and diagnosis |
| 06/06/2013 | US20130142865 Fixed dosing of her antibodies |
| 06/06/2013 | US20130142861 Compositions And Method For Detecting And Treating Abnormal Liver Homeostasis And Hepatocarcinogenesis |
| 06/06/2013 | US20130142839 Method and system for adding sensory conditioning cues in a pharmacotherapeutic regimen |
| 06/06/2013 | US20130142838 Compositions containing micronized tanaproget prepared by wet granulation |
| 06/06/2013 | US20130142815 Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase |
| 06/06/2013 | US20130142809 METHODS OF TREATMENT USING AN IFN gamma INHIBITOR |
| 06/06/2013 | US20130142789 Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies |
| 06/06/2013 | US20130142787 Therapeutic Use of Anti-CD22 Antibodies for Inducing Trogocytosis |
| 06/06/2013 | US20130142758 Novel hydroxamates as therapeutic agents |
| 06/06/2013 | US20130142757 Pyrazole derivatives |
| 06/06/2013 | US20130142756 Methods of improving central nervous system functioning |
| 06/06/2013 | US20130142730 Compounds and methods for the treatment of cancer |
| 06/06/2013 | CA2857159A1 Drug containing carrier into cell for forming immune complex |
| 06/05/2013 | EP2600154A1 Method for generating data set for integrated proteomics, integrated proteomics method using data set for integrated proteomics that is generated by the generation method, and method for identifying causative substance using same |
| 06/05/2013 | EP2599499A1 Use of pyrimidine derivatives for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members |
| 06/05/2013 | EP2599498A1 Composition for ophthalmic disease associated with hypoxia or ischemia |
| 06/05/2013 | EP2599487A1 Therapeutic agent or prophylactic agent for neuropathic pain |
| 06/05/2013 | EP2599475A2 Pharmaceutical composition having desirable bioavailability |
| 06/05/2013 | EP2598168A2 Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor |
| 06/05/2013 | EP2598153A1 Synthetic synovial fluid compositions and methods for making the same |
| 06/05/2013 | EP2598151A1 Compositions for treating heartworm infestation |
| 06/05/2013 | EP2598139A2 Compositions and methods for enhancing the effectiveness of systemic, hipec, ip, and related cancer treatments |
| 06/05/2013 | EP2598132A1 Composition for the treatment and prevention of herpes simplex labialis |
| 06/05/2013 | EP2598119A2 Preservative free brimonidine and timolol solutions |
| 06/05/2013 | EP2598118A2 Preservative free bimatoprost and timolol solutions |
| 06/05/2013 | CN202961236U Medicine patch used for nursing in dialysis department |
| 06/05/2013 | CN103140242A Composition for oral use |
| 06/05/2013 | CN103140224A An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
| 06/05/2013 | CN103130966A A silicone acrylate hybrid composition and method of making same |
| 06/05/2013 | CN103130775A Indolinone derivatives serving as tyrosine kinase inhibitors |
| 06/05/2013 | CN103127513A Alpha-glycosidase inhibitor and hydroxymethyl glutaryl coenzyme A reductase inhibitor composition for treating diabetes and complications |
| 06/05/2013 | CN103127512A Novel drug composition for curing hepatitis B virus |
| 06/05/2013 | CN103127511A Novel drug composition for curing hepatitis c virus |
| 06/05/2013 | CN103127510A Medicine composition containing hepatic cell growth factor receptor inhibitor and Bcl-2 inhibitor and application thereof |
| 06/05/2013 | CN103127509A Medicine composition and preparation method and purpose |
| 06/05/2013 | CN103127508A Herba lycopi containing compound composition for treating escherichia coli infected diseases of livestock and poultry |
| 06/05/2013 | CN103127507A Holly bark containing compound composition for treating escherichia coli infected diseases of livestock and poultry |
| 06/05/2013 | CN103127506A Core/shell structured magnetic meso-porous biological active glass microsphere material and its preparation method |
| 06/05/2013 | CN103127505A Uses of statin compound serving as partly used medicine for curing diabetes mellitus |
| 06/05/2013 | CN103127504A Compositions and methods for topical nitric oxide generation |
| 06/05/2013 | CN103127503A Application of antagonizing and/or blocking IL-6/IL-6R/gp130 signaling pathway in treatment of anti-hepatoma |
| 06/05/2013 | CN103127492A Anti-hepatitis C virus protein and application thereof |
| 06/05/2013 | CN103127036A Method for preparing film agent by using chitosan and Arabic gum as matrix |
| 06/05/2013 | CN103127034A Mouth mucosa drug sustained release preparation for treating mouth periodontal disease by doxycycline |
| 06/05/2013 | CN103127031A Preparation method for oily and oil soluble drug nanocapsules |
| 06/05/2013 | CN103126975A Preparation method of hydrogel patch substrate with gradient drug concentration |
| 06/05/2013 | CN103125933A Liver and gallbladder calculus removing product |
| 06/05/2013 | CN102372773B Human bladder cancer tumor marker, antibody thereof and application thereof |
| 06/05/2013 | CN102100913B Target spot and medicine for treating cerebral injury |
| 06/05/2013 | CN101678106B Combination of Blys inhibition and/or APRIL inhibition and immunnosuppressants for treatment of autoimmune disease |
| 06/05/2013 | CN101654672B RNA interference mediating small RNA molecules |
| 06/05/2013 | CN101580871B Method for screening new drug for lowering cholesterol based on analysis of change of NPC1L1 protein subcellular localization |
| 06/05/2013 | CN101155923B Method for producing probiotically derived compounds |